Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial

BACKGROUND: Radioiodine‐refractory differentiated thyroid cancer (RAI‐R DTC) is an aggressive form of thyroid cancer. Lenvatinib is a multikinase inhibitor approved for treatment of RAI‐R DTC. The impact of tumor response and tumor burden on overall survival (OS) after lenvatinib treatment in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiyota, Naomi, Tahara, Makoto, Robinson, Bruce, Schlumberger, Martin, Sherman, Steven I., Leboulleux, Sophie, Lee, Eun Kyung, Suzuki, Takuya, Ren, Min, Fushimi, Kazuma, Wirth, Lori J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325449/
https://www.ncbi.nlm.nih.gov/pubmed/35380178
http://dx.doi.org/10.1002/cncr.34181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325449/
https://www.ncbi.nlm.nih.gov/pubmed/35380178
http://dx.doi.org/10.1002/cncr.34181

Ejemplares similares